Showing results (1951-1960 of 2,286) with videos related to

Sort By:
Pageof 229
Journal of Neuro-Oncology|October 12, 2011
Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastomaDavid A Reardon, Annick Desjardins, Katherine B Peters, et al.
Genes & Cancer|July 24, 2014
Amphiregulin and PTEN evoke a multimodal mechanism of acquired resistance to PI3K inhibitionKyle A Edgar, Lisa Crocker, Eric Cheng, et al.
Emerging Infectious Diseases|December 22, 2020
Etiology of Severe Acute Respiratory Infections, Bangladesh, 2017Md R Rahaman, Karen A Alroy, Chris A Van Beneden, et al.
Occupational and Environmental Medicine|February 12, 2022
Prevalence and severity of abnormal lung function among US former coal miners with and without radiographic coal workers' pneumoconiosisLeonard H T Go, Kirsten S Almberg, Cecile S Rose, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 15, 2000
Unarmed, tumor-specific monoclonal antibody effectively treats brain tumorsJ H Sampson, L E Crotty, S Lee, et al.
Neuro-Oncology|August 19, 2010
Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant gliomaSith Sathornsumetee, Annick Desjardins, James J Vredenburgh, et al.
American Journal of Ophthalmology|July 7, 2020
Incidence and Outcome of Uveitic Glaucoma in Eyes With Intermediate, Posterior, or Panuveitis Followed up to 10 Years After Randomization to Fluocinolone Acetonide Implant or Systemic TherapyJohn H Kempen, Mark L Van Natta, David S Friedman, et al.
Neuro-Oncology Practice|March 18, 2024
Use, access, and initial outcomes of off-label ivosidenib in patients with IDH1 mutant gliomaKatherine B Peters, Candice Alford, Amy Heltemes, et al.
Cancer|February 29, 2012
Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade gliomaDavid A Reardon, Annick Desjardins, James J Vredenburgh, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|January 12, 2010
Measuring the rate of progression in Friedreich ataxia: implications for clinical trial designLisa S Friedman, Jennifer M Farmer, Susan Perlman, et al.
Pageof 229